Aprea Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Aprea Therapeutics, Inc. carries a market capitalization of 4.95M, placing it among publicly traded companies globally. Its enterprise value stands at -39.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.95M |
| Enterprise Value | -39.82M |
Share Statistics
Aprea Therapeutics, Inc. currently has 11.98M shares outstanding.
| Shares Outstanding | 11.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | -0.55 |
| P/OCF Ratio | -0.55 |
Financial Position
Aprea Therapeutics, Inc. maintains a current ratio of 8.92, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.92 |
| Quick Ratio | 8.77 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -35.25 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aprea Therapeutics, Inc.'s stock has declined approximately -57.90055% over the past 52 weeks. The 50-day moving average sits at 0.84, while the 200-day moving average is 1.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | -57.90055% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 1.07 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.56M, while operating income came in at -12.58M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.58M |
| Pretax Income | -11.95M |
| Net Income | -11.95M |
| EBITDA | -12.56M |
| EBIT | -12.58M |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
Total book value stands at -336.92M, with working capital of 41.95M providing operational flexibility.
| Cash & Cash Equivalents | 46.47M |
| Total Debt | N/A |
| Net Debt | -46.47M |
| Equity (Book Value) | -336.92M |
| Book Value Per Share | -38.69 |
| Working Capital | 41.95M |
Cash Flow
Aprea Therapeutics, Inc. produced -12.02M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.02M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.02M |
| FCF Per Share | -1.38 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -590.23 |
| FCF Yield | -180.95 |
Stock Splits
Aprea Therapeutics, Inc.'s most recent stock split took place on February 13, 2023 with a 20:1 split ratio.
| Last Split Date | 2/13/2023 |
| Split Ratio | 20:1 |
Scores
Aprea Therapeutics, Inc. posts an Altman Z-Score of -9.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.06 |